Indianapolis, Indiana – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) hosted its Q4 2024 Earnings Conference Call on March 27, 2025, at 8:00 AM ET. The company’s key executives, including Head of Investor Relations Alex Braun, CEO Dan O’Connell, CFO and Chief Business Officer Matt Zuga, President and Chief Development Officer Jim Doherty, and Chief Medical Officer Eric Siemers, were present during the call.

During the conference call, Alex Braun initiated the session by welcoming participants and introducing the members of the Acumen Pharmaceuticals team. He highlighted the purpose of the call – to discuss the company’s business update and financial results for the quarter ending on December 31, 2024. Braun encouraged listeners to refer to the company’s official press release on their website for additional information on the topics to be discussed.

CEO Dan O’Connell and CFO Matt Zuga took the floor to deliver their prepared remarks, addressing the financial performance and future plans of Acumen Pharmaceuticals. Following their presentations, the call was opened for a question-and-answer session, where participants, including representatives from Bank of America, Cantor Fitzgerald, UBS, BTIG, and H. C. Wainwright & Company, posed queries to the Acumen team.

Throughout the call, forward-looking statements regarding the company’s financial outlook and business strategies were made, in accordance with federal securities laws. These statements were accompanied by a reminder of the potential risks and uncertainties that could impact the realization of these plans. The executives stressed the importance of transparency and encouraged stakeholders to stay informed by accessing the information provided on the Acumen website.